<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:05:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10199351" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10199351</identifier>
        <datestamp>2023-05-21</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10199351</article-id>
              <article-id pub-id-type="pmcid">PMC10199351</article-id>
              <article-id pub-id-type="pmc-uid">10199351</article-id>
              <article-id pub-id-type="pmid">37204788</article-id>
              <article-id pub-id-type="pmid">37204788</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.14443</article-id>
              <article-id pub-id-type="publisher-id">zoi230445</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Cardiology</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit</article-title>
                <subtitle>A Secondary Analysis of the SPRINT Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit</alt-title>
                <alt-title alt-title-type="running-head">Identifying Patients for Intensive Blood Pressure Treatment Based on Cognitive Benefit</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Ghazi</surname>
                    <given-names>Lama</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shen</surname>
                    <given-names>Jincheng</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ying</surname>
                    <given-names>Jian</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Derington</surname>
                    <given-names>Catherine G.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230445aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cohen</surname>
                    <given-names>Jordana B.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MSCE</degrees>
                  <xref rid="zoi230445aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="zoi230445aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marcum</surname>
                    <given-names>Zachary A.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Herrick</surname>
                    <given-names>Jennifer S.</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi230445aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi230445aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>King</surname>
                    <given-names>Jordan B.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230445aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi230445aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cheung</surname>
                    <given-names>Alfred K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230445aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="zoi230445aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Williamson</surname>
                    <given-names>Jeff D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>MHS</degrees>
                  <xref rid="zoi230445aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pajewski</surname>
                    <given-names>Nicholas M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bryan</surname>
                    <given-names>Nick</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Supiano</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230445aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sonnen</surname>
                    <given-names>Josh</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230445aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weintraub</surname>
                    <given-names>William S.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230445aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greene</surname>
                    <given-names>Tom H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230445aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bress</surname>
                    <given-names>Adam P.</given-names>
                  </name>
                  <degrees>PharmD</degrees>
                  <degrees>MS</degrees>
                  <xref rid="zoi230445aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="zoi230445aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi230445aff1"><label>1</label>Department of Epidemiology, School of Public Health, University of Alabama at Birmingham</aff>
              <aff id="zoi230445aff2"><label>2</label>Department of Family and Preventive Medicine, University of Utah, Salt Lake City</aff>
              <aff id="zoi230445aff3"><label>3</label>Department of Internal Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City</aff>
              <aff id="zoi230445aff4"><label>4</label>Intermountain Healthcare Department of Population Health Sciences, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City</aff>
              <aff id="zoi230445aff5"><label>5</label>Department of Medicine, Renal-Electrolyte and Hypertension Division, Perelman School of Medicine at the University of Pennsylvania, Philadelphia</aff>
              <aff id="zoi230445aff6"><label>6</label>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff>
              <aff id="zoi230445aff7"><label>7</label>Department of Pharmacy, University of Washington School of Pharmacy, Seattle</aff>
              <aff id="zoi230445aff8"><label>8</label>George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah</aff>
              <aff id="zoi230445aff9"><label>9</label>Institute for Health Research, Kaiser Permanente Colorado, Aurora</aff>
              <aff id="zoi230445aff10"><label>10</label>The Sticht Center for Healthy Aging and Alzheimer’s Prevention, Wake Forest School of Medicine, Winston-Salem, North Carolina</aff>
              <aff id="zoi230445aff11"><label>11</label>Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina</aff>
              <aff id="zoi230445aff12"><label>12</label>Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia</aff>
              <aff id="zoi230445aff13"><label>13</label>Division of Geriatrics, University of Utah School of Medicine, and The Center on Aging, University of Utah, Salt Lake City</aff>
              <aff id="zoi230445aff14"><label>14</label>Department of Pathology and Neurology and Neurosurgery, McGill University School of Medicine, Montreal, Quebec, Canada</aff>
              <aff id="zoi230445aff15"><label>15</label>MedStar Health Research Institute and Georgetown University, Washington, DC</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> March 25, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> May 19, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.14443</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Ghazi L et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi230445cor1"><bold>Corresponding Author:</bold> Lama Ghazi, MD, PhD, Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 1665 University Blvd, Room 210D, Birmingham, AL 35233 (<email xlink:href="lghazi@uab.edu">lghazi@uab.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Shen and Ying had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Ghazi, Shen, Derington, Cohen, Williamson, Pajewski, Bryan, Weintraub, Bress.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Ghazi, Shen, Ying, Cohen, Marcum, Herrick, King, Cheung, Williamson, Pajewski, Bryan, Supiano, Sonnen, Greene, Bress.</p>
                <p><italic>Drafting of the manuscript:</italic> Ghazi, Weintraub, Bress.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Ghazi, Shen, Ying, Derington, Cohen, Marcum, Herrick, King, Cheung, Williamson, Pajewski, Bryan, Supiano, Sonnen, Greene, Bress.</p>
                <p><italic>Statistical analysis:</italic> Shen, Ying, Greene, Bress.</p>
                <p><italic>Obtained funding:</italic> Cheung, Williamson, Bryan, Bress.</p>
                <p><italic>Administrative, technical, or material support:</italic> Shen, Derington, Marcum, Williamson, Bryan, Sonnen, Weintraub.</p>
                <p><italic>Supervision:</italic> Cohen, Pajewski, Bryan, Supiano.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This project was supported by grants R01AG065805 and R01AG055606 from the National Institute on Aging (NIA) of the National Institutes of Health (NIH); grant K76AG059929 from the NIA (Dr Marcum); grants K23-HL133843, R01-HL153646, R01-HL157108, R01-HL155599, R01-HL157264, and U01-HL160277 from the National Heart, Lung, and Blood Institute (NHLBI) (Dr Cohen); grant U01-TR003734 from the National Center for Advancing Translational Sciences (Dr Cohen); grants R01-DK123104 and U24-DK060990 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Dr Cohen); and the Bugher Foundation Award from the American Heart Association (Dr Cohen). The Systolic Blood Pressure Intervention Trial (SPRINT) was supported by contracts HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, and HHSN268200900049C and interagency agreement A-HL-13-002-001 from the NHLBI, the NIDDK, the NIA, and the National Institute of Neurological Disorders and Stroke and in part with resources and use of facilities through the Department of Veterans Affairs (VA). Azilsartan and chlorthalidone (combined with azilsartan) were provided by Takeda Pharmaceuticals International Inc. Additional support was provided through clinical and translational science awards UL1TR000439 (Case Western Reserve University); UL1RR025755 (The Ohio State University); UL1RR024134 and UL1TR000003 (University of Pennsylvania); UL1RR025771 (Boston University); UL1TR000093 (Stanford University); UL1RR025752, UL1TR000073, and UL1TR001064 (Tufts University); UL1TR000050 (University of Illinois); UL1TR000005 (University of Pittsburgh); 9U54TR000017-06 (The University of Texas Southwestern Medical Center); UL1TR000105-05 (University of Utah); UL1 TR000445 (Vanderbilt University); UL1TR000075 (George Washington University); UL1 TR000002 (University of California, Davis); UL1 TR000064 (University of Florida); and UL1TR000433 (University of Michigan) from the National Center for Advancing Translational Sciences and by Centers of Biomedical Research Excellence award P30GM103337 from the National Institute of General Medical Sciences (Tulane University). The support and resources from the Center for High Performance Computing at the University of Utah are gratefully acknowledged.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p><bold>Disclaimer:</bold> The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the VA.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> The authors thank the other investigators, the staff, and the participants of SPRINT for their valuable contributions. A full list of participating SPRINT investigators and institutions and further information about the study can be found at <ext-link xlink:href="https://www.sprinttrial.org/public/dspHome.cfm" ext-link-type="uri">https://www.sprinttrial.org/public/dspHome.cfm</ext-link>.</p>
                <p><bold>Additional Information:</bold> Coauthor Jennifer S. Herrick, MS, died on February 26, 2023. Our deepest condolences to her family and loved ones.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-05-19T10:00">
                <day>19</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>19</day>
                <month>5</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>5</issue>
              <elocation-id>e2314443</elocation-id>
              <history>
                <date date-type="received">
                  <day>24</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>3</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Ghazi L et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e2314443.pdf">jamanetwopen-e2314443.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.14443"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi230445-1">
                  <title>Question</title>
                  <p>How does the magnitude of projected cognitive benefit from intensive vs standard systolic blood pressure (SBP) treatment vary across patients?</p>
                </sec>
                <sec id="ab-zoi230445-2">
                  <title>Findings</title>
                  <p>In this secondary analysis of 7918 participants in the Systolic Blood Pressure Intervention Trial with a median follow-up of 4 years, participants with higher baseline risk of probable dementia or amnestic mild cognitive impairment (MCI) gained greater absolute cognitive benefit from intensive vs standard SBP treatment.</p>
                </sec>
                <sec id="ab-zoi230445-3">
                  <title>Meaning</title>
                  <p>These findings suggest that intensive SBP treatment reduces the risk of combined MCI or dementia overall and to a greater degree among those with higher baseline risk of MCI or dementia in a monotonic fashion.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This secondary analysis of the randomized clinical Systolic Blood Pressure Intervention Trial (SPRINT) develops a model to estimate the patient-specific benefits of intensive vs standard systolic blood pressure (SBP) treatment among adults with high cardiovascular risk.</p>
              </abstract>
              <abstract>
                <sec id="ab-zoi230445-4">
                  <title>Importance</title>
                  <p>Intensive vs standard treatment to lower systolic blood pressure (SBP) reduces risk of mild cognitive impairment (MCI) or dementia; however, the magnitude of cognitive benefit likely varies among patients.</p>
                </sec>
                <sec id="ab-zoi230445-5">
                  <title>Objective</title>
                  <p>To estimate the magnitude of cognitive benefit of intensive vs standard systolic BP (SBP) treatment.</p>
                </sec>
                <sec id="ab-zoi230445-6">
                  <title>Design, Setting, and Participants</title>
                  <p>In this ad hoc secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT), 9361 randomized clinical trial participants 50 years or older with high cardiovascular risk but without a history of diabetes, stroke, or dementia were followed up. The SPRINT trial was conducted between November 1, 2010, and August 31, 2016, and the present analysis was completed on October 31, 2022.</p>
                </sec>
                <sec id="ab-zoi230445-7">
                  <title>Intervention</title>
                  <p>Systolic blood pressure treatment to an intensive (&lt;120 mm Hg) vs standard (&lt;140 mm Hg) target.</p>
                </sec>
                <sec id="ab-zoi230445-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The primary outcome was a composite of adjudicated probable dementia or amnestic MCI.</p>
                </sec>
                <sec id="ab-zoi230445-9">
                  <title>Results</title>
                  <p>A total of 7918 SPRINT participants were included in the analysis; 3989 were in the intensive treatment group (mean [SD] age, 67.9 [9.2] years; 2570 [64.4%] men; 1212 [30.4%] non-Hispanic Black) and 3929 were in the standard treatment group (mean [SD] age, 67.9 [9.4] years; 2570 [65.4%] men; 1249 [31.8%] non-Hispanic Black). Over a median follow-up of 4.13 (IQR, 3.50-5.88) years, there were 765 and 828 primary outcome events in the intensive treatment group and standard treatment group, respectively. Older age (hazard ratio [HR] per 1 SD, 1.87 [95% CI, 1.78-1.96]), Medicare enrollment (HR per 1 SD, 1.42 [95% CI, 1.35-1.49]), and higher baseline serum creatinine level (HR per 1 SD, 1.24 [95% CI, 1.19-1.29]) were associated with higher risk of the primary outcome, while better baseline cognitive functioning (HR per 1 SD, 0.43 [95% CI, 0.41-0.44]) and active employment status (HR per 1 SD, 0.44 [95% CI, 0.42-0.46]) were associated with lower risk of the primary outcome. Risk of the primary outcome by treatment goal was estimated accurately based on similar projected and observed absolute risk differences (C statistic = 0.79). Higher baseline risk for the primary outcome was associated with greater benefit (ie, larger absolute reduction of probable dementia or amnestic MCI) of intensive vs standard treatment across the full range of estimated baseline risk.</p>
                </sec>
                <sec id="ab-zoi230445-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this secondary analysis of the SPRINT trial, participants with higher baseline projected risk of probable dementia or amnestic MCI gained greater absolute cognitive benefit from intensive vs standard SBP treatment in a monotonic fashion.</p>
                </sec>
                <sec id="ab-zoi230445-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01206062" ext-link-type="uri">NCT01206062</ext-link></p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI230445">
              <title>Introduction</title>
              <p>In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive (systolic blood pressure [SBP] goal &lt;120 mm Hg) vs standard (SBP goal &lt;140 mm Hg) treatment reduced the risk of a composite outcome of mild cognitive impairment (MCI) and probable dementia, in addition to cardiovascular disease (CVD) and all-cause mortality.<sup><xref rid="zoi230445r1" ref-type="bibr">1</xref>,<xref rid="zoi230445r2" ref-type="bibr">2</xref></sup> While Williamson et al<sup><xref rid="zoi230445r1" ref-type="bibr">1</xref></sup> have previously shown that intensive treatment reduced the risk of MCI or probable dementia overall on average, the study did not address treatment effect heterogeneity and which populations derive the greatest absolute benefit for prioritization. As we have previously seen, the magnitude of absolute benefit from intensive treatment for CVD outcomes was greatest for those at highest baseline CVD risk, and this population should initially be targeted.<sup><xref rid="zoi230445r3" ref-type="bibr">3</xref></sup> As such, cognitive benefit from intensive vs standard SBP treatment may vary among patients.</p>
              <p>Detecting patient characteristics associated with the greatest magnitude of cognitive benefit from intensive vs standard SBP treatment may help prioritize patients, as the intensive treatment component requires additional health care resources (clinical time, office and laboratory visits, and medications) and increases the risk of mostly mild, transient treatment-related adverse events.<sup><xref rid="zoi230445r4" ref-type="bibr">4</xref></sup> Two broad classes of statistical approaches are currently being used to identify patient subgroups with higher or lower predicted magnitude of benefit from a treatment in a randomized clinical trial: effect modeling and risk modeling.<sup><xref rid="zoi230445r5" ref-type="bibr">5</xref></sup> Effect modeling uses regression with interaction terms between the randomized treatment and baseline covariates to identify subgroups with varying treatment effects, usually on a risk ratio or hazard ratio (HR) scale. In contrast, risk modeling explores how the absolute benefit of treatment (ie, the absolute risk reduction of cognitive outcomes), the most clinically relevant effect measure, varies as a function of the baseline risk of the outcome (a function of many baseline factors assessed simultaneously), which usually varies substantially within a clinical trial population. This approach has been termed <italic>risk magnification</italic> of the treatment effect. Unlike CVD risk, standardized, validated, and widely compatible risk prediction models for cognitive impairment are lacking. We developed an internal multivariable model to estimate patient-specific magnitude of benefits of intensive vs standard SBP treatment on cognitive outcomes in SPRINT participants using a risk-modeling approach.</p>
            </sec>
            <sec id="H1-2-ZOI230445">
              <title>Methods</title>
              <sec id="H2-1-ZOI230445">
                <title>SPRINT Design</title>
                <p>The SPRINT design, rationale, and main results have been published previously,<sup><xref rid="zoi230445r1" ref-type="bibr">1</xref>,<xref rid="zoi230445r2" ref-type="bibr">2</xref>,<xref rid="zoi230445r6" ref-type="bibr">6</xref></sup> and the trial protocol is provided in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 1</xref>. This study was reviewed and approved by the University of Utah Institutional Review Board. The study protocols for SPRINT and the included cohorts were approved by the institutional review boards at each participating institution, and all participants provided written informed consent. We followed the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) reporting guideline for randomized clinical trials.</p>
                <p>Briefly, SPRINT recruited participants 50 years or older with increased cardiovascular risk and an SBP between 130 to 180 mm Hg, depending on the number of antihypertensive medications used. Those with a history of stroke, heart failure, standing BP less than 110 mm Hg, diabetes, estimated glomerular filtration rate less than 20 mL/min/1.73m<sup>2</sup>, and dementia were excluded. Participants were randomized to target an intensive (SBP &lt;120 mm Hg) or a standard (SBP &lt;140 mm Hg) treatment goal. SPRINT enrolled patients between November 1, 2010, and March 31, 2013, and was completed on August 31, 2016. Cognitive assessments were continued through July 30, 2018, and the present analysis was completed on October 31, 2022.</p>
              </sec>
              <sec id="H2-2-ZOI230445">
                <title>Study Population for the Current Analysis</title>
                <p>We excluded participants without a cognitive assessment during follow-up (643 of 9631 randomized [6.7%]) or who had missing values of baseline covariates. Our study population included 7918 SPRINT participants, 3989 in the intensive treatment group and 3929 in the standard treatment group (<xref rid="zoi230445f1" ref-type="fig">Figure 1</xref>).</p>
                <fig position="float" id="zoi230445f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Participant Eligibility, Randomization, and Follow-up</title>
                    <p>CVD indicates cardiovascular disease; SBP, systolic blood pressure.</p>
                    <p><sup>a</sup>One participant contributed twice to the exclusion criteria.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2314443-g001" position="float"/>
                </fig>
              </sec>
              <sec id="H2-3-ZOI230445">
                <title>Ascertainment of MCI and Probable Dementia</title>
                <p>In SPRINT, cognitive screening assessments were administered at baseline, 2 and 4 years of follow up, study closeout (if it was &gt;1 year from the 4-year visit), and an extended follow-up visit between October 1, 2017, and July 30, 2018 (eFigure 1 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). Assessments were performed by certified examiners at local study sites.</p>
                <p>Cognitive assessment in SPRINT included a screening battery administered to all participants: (1) Montreal Cognitive Assessment for global cognitive function; (2) Logical Memory forms I and II subtests of the Wechsler Memory Scale for learning and memory; and (3) Digit Symbol Coding Test of the Wechsler Adult Intelligence Scale for processing speed.<sup><xref rid="zoi230445r7" ref-type="bibr">7</xref>,<xref rid="zoi230445r8" ref-type="bibr">8</xref>,<xref rid="zoi230445r9" ref-type="bibr">9</xref></sup> For participants scoring below prespecified cutoffs adjusted for age, race and ethnicity, culture, and educational level, an extended cognitive assessment battery was also administered. A Functional Activities Questionnaire of 10 items to measure functional abilities was administered to a preidentified proxy for participants with a low score on any of the screening tests<sup><xref rid="zoi230445r10" ref-type="bibr">10</xref></sup> (eMethods and eTable 1 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). For participants who could not be assessed in person during follow-up, a validated telephone battery test was administered. If participants scored at or below 31 on the Modified Telephone Interview for Cognitive Status, the participant’s proxy was administered the Functional Activities Questionnaire.<sup><xref rid="zoi230445r11" ref-type="bibr">11</xref></sup> However, if a participant died or was unable to communicate by telephone, a prespecified proxy was administered the Dementia Questionnaire.<sup><xref rid="zoi230445r12" ref-type="bibr">12</xref></sup> All participants were given standardized questionnaires of depressive status, perceived health status, quality of life, and self-reported medications, medical problems, and health habits (ie, smoking, alcohol use, physical activity).<sup><xref rid="zoi230445r13" ref-type="bibr">13</xref></sup> Cognitive status was adjudicated by 2 blinded experts using standardized classified criteria. Disagreements were discussed and adjudicated by a full panel. Participants were classified as having no cognitive impairment, MCI (amnestic or nonamnestic), probable dementia, or cannot classify.</p>
              </sec>
              <sec id="H2-4-ZOI230445">
                <title>Outcomes</title>
                <p>Our primary outcome for this analysis was a composite of adjudicated probable dementia or amnestic MCI. We chose to include amnestic MCI instead of any MCI for the following reasons. The definition of MCI in the original SPRINT protocol (ie, protocol-defined MCI) required 2 consecutive occurrences of MCI (amnestic or nonamnestic). For this analysis, to avoid conditioning the MCI outcome on future cognitive assessments and to include as many MCI events as possible, we chose to analyze the first occurrence of amnestic MCI, which has been consistently associated with the highest increased risk of progression to dementia.<sup><xref rid="zoi230445r14" ref-type="bibr">14</xref>,<xref rid="zoi230445r15" ref-type="bibr">15</xref>,<xref rid="zoi230445r16" ref-type="bibr">16</xref></sup> Secondary outcomes included occurrence of (1) probable dementia, amnestic MCI, or death; (2) probable dementia or death; and (3) probable dementia, protocol-defined MCI, or death. We also considered a broader definition of MCI as the first-time occurrence of any adjudicated MCI and assessed the occurrence of the composite outcome of protocol-defined MCI, probable dementia, or death.</p>
              </sec>
              <sec id="H2-5-ZOI230445">
                <title>Covariates</title>
                <p>To develop the multivariable model, we identified 58 candidate baseline covariates considered likely to be associated with cognitive function based on expert opinion (L.G., J.D.W., M.S., and A.P.B.) and published literature.<sup><xref rid="zoi230445r17" ref-type="bibr">17</xref>,<xref rid="zoi230445r18" ref-type="bibr">18</xref>,<xref rid="zoi230445r19" ref-type="bibr">19</xref>,<xref rid="zoi230445r20" ref-type="bibr">20</xref>,<xref rid="zoi230445r21" ref-type="bibr">21</xref>,<xref rid="zoi230445r22" ref-type="bibr">22</xref>,<xref rid="zoi230445r23" ref-type="bibr">23</xref>,<xref rid="zoi230445r24" ref-type="bibr">24</xref>,<xref rid="zoi230445r25" ref-type="bibr">25</xref>,<xref rid="zoi230445r26" ref-type="bibr">26</xref></sup> These covariates comprised demographic, social, clinical, laboratory, and medication variables at the SPRINT baseline visit (ie, prerandomization). Race and ethnicity were self-reported in SPRINT, and these variables were included because previous trials have identified racial differences in cognitive outcomes, and this merited inclusion in the current studies. Additionally, the National Institutes of Health requires the inclusion of race and ethnicity in clinical trials. These groups included Hispanic, non-Hispanic Black, non-Hispanic White, and other (comprising American Indian and Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and other race or ethnicity). For statistical purposes, race was categorized as Black vs non-Black participants, with the non-Black category comprising Hispanic, White, and other race categories. Additionally, clinicians with expertise in hypertension and dementia subject matter selected covariates that are likely to be available at the point of care—that is, at the time clinicians discuss decisions about intensive SBP treatment with their eligible patients (basic reduced set in eTable 2 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). We identified 3 different covariate sets to assess the information we can recover from our estimation model under a range of scenarios in clinical and research practice (eTable 2 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). The first covariate set (full set) included all candidate covariates. The second covariate set (augmented reduced set) included only covariates known to be associated with cognitive function regardless of whether these covariates are readily available in discrete data fields at the point of care. The final covariate set (basic reduced set) only included covariates that are available at the point of care and can be easily obtained in discrete data fields in the primary care setting. This prioritization was also informed by the national patient-centered clinical research network PCORnet Common Data Model variable list, version 6.0 (ie, representing structured data elements commonly available in US health system electronic health record databases).<sup><xref rid="zoi230445r27" ref-type="bibr">27</xref></sup></p>
              </sec>
              <sec id="H2-6-ZOI230445">
                <title>Statistical Analysis</title>
                <p>We described the association of each covariate with each of the cognitive outcomes using bar plots of HRs (expressed relative to 1-SD increases in the covariates). We used univariable Cox proportional hazards regressions of each outcome onto each covariate, separately.</p>
                <sec id="H3-1-ZOI230445">
                  <title>Estimation Model Development</title>
                  <p>We fit a modified elastic-net Cox proportional hazards regression model for the projection of each outcome using the 3 covariate sets separately (full set, augmented reduced set, and basic reduced set).<sup><xref rid="zoi230445r28" ref-type="bibr">28</xref></sup> The elastic net is a machine learning method for regression analysis that seeks to provide accurate estimation from a large number of possibly correlated covariates (estimation variables) by balancing estimation accuracy with a term that penalizes excessively large regression coefficients based on correlation between the estimation variables. To allow for potential heterogeneity in the treatment effect of intensive vs standard treatment across the full range of baseline risk, we modified the standard elastic-net procedure to simultaneously estimate a numerical baseline risk score for each cognitive outcome as well as its interaction with the treatment groups (intensive vs standard). In this way, for each cognitive outcome and each of the 3 covariate sets, the analysis produced both a baseline risk score that estimates the overall risk of the cognitive outcome across the 2 treatment groups as well as the dose-response association between the baseline risk score and the treatment effect expressed as the difference in the absolute risk of the cognitive outcome between the treatment groups. To improve accuracy, our model requires that the difference in absolute risks must approach 0 as the baseline risk score approaches 0. We presented graphical displays of the association between the estimated risk difference and the baseline risk score under the modified elastic-net model (which we refer to as risk magnification plots) to illustrate the consequences of risk amplification on the treatment effect. All absolute risks used in computing the risk differences were estimated at 4.13 years, the median follow-up time in SPRINT for cognitive outcomes.</p>
                </sec>
                <sec id="H3-2-ZOI230445">
                  <title>Adequacy of Estimation Models for the Risks of the Cognitive Outcomes</title>
                  <p>We evaluated the adequacy of our models for estimating risk of cognitive outcomes by providing standard measures of discrimination and calibration. The concordance (or C) statistic was used to assess discrimination, which evaluates the models’ ability to distinguish between patients with higher vs lower risks for the cognitive outcomes.<sup><xref rid="zoi230445r29" ref-type="bibr">29</xref>,<xref rid="zoi230445r30" ref-type="bibr">30</xref></sup> A C statistic of 0.5 indicates random concordance, while a C statistic of approximately 0.8 is commonly thought of as a threshold of clinical relevant estimation. We visually displayed model calibration by comparing the observed risk of a given outcome (estimating directly using a Kaplan-Meier curve) with the mean estimated risk under the model across subgroups defined by the deciles of estimated risks. With these plots, we provided the mean of the absolute errors (MAE)<sup><xref rid="zoi230445r30" ref-type="bibr">30</xref>,<xref rid="zoi230445r31" ref-type="bibr">31</xref></sup> (the absolute difference between the observed and estimated risks) across the 10 deciles as a numerical calibration measure. The smaller the MAE, the lower the error and the better the model calibration. We also provided <italic>P</italic> values from the Greenwood-Nam-D’Agostino test (GND),<sup><xref rid="zoi230445r30" ref-type="bibr">30</xref>,<xref rid="zoi230445r31" ref-type="bibr">31</xref></sup> which assesses whether the deviation between the observed and estimated risks of the outcome under the model is larger than expected by chance. A nonsignificant GND <italic>P</italic> value (<italic>P</italic> &gt; .05) indicated that the data were consistent with proper calibration.</p>
                </sec>
                <sec id="H3-3-ZOI230445">
                  <title>Adequacy of the Estimation Models for Differences in Risk Between Treatment Groups</title>
                  <p>For each cognitive outcome and for each covariate set, we summarized the adequacy of the modified elastic-net model to estimate the risk differences in the cognitive outcome between treatment groups by dividing the cohort into tertiles of the estimated risk differences and comparing the observed risk differences (estimated from the Kaplan-Meier curves within tertiles at 4.13 years) to the estimated risk differences under the model. We report the observed risk differences in association with the estimated risk differences on the aforementioned risk amplification plots, where the 95% CIs for the observed risk differences are marked for all tertiles.</p>
                </sec>
                <sec id="H3-4-ZOI230445">
                  <title>Evaluating Effect Modeling in Addition to Risk Modeling</title>
                  <p>We also tested a hybrid risk-modeling and effect-modeling approach by adding interaction terms between treatment assignment and prespecified subgroups to the elastic-net Cox proportional hazards regression models (eMethods in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). These included age (&lt;75 vs ≥75 years), sex (women vs men), race (Black vs non-Black), baseline MCI (with vs without), and baseline CVD (with vs without). This analysis addressed whether adding interactions of treatment group with these prespecified baseline factors improved the modified elastic-net Cox proportional hazards regression models’ ability to estimate cognitive treatment benefit. These analyses were repeated for all outcomes. Analyses were performed in SAS, version 9.4 (SAS Institute Inc), and R, version 3.5.1 (R Project for Statistical Computing). The R code to estimate cognitive benefit using baseline covariates is available elsewhere.<sup><xref rid="zoi230445r32" ref-type="bibr">32</xref></sup></p>
                </sec>
              </sec>
            </sec>
            <sec id="H1-3-ZOI230445">
              <title>Results</title>
              <p>Of 8451 SPRINT participants randomized with complete baseline and follow-up cognitive assessment data, 7918 were included in the present analysis. Of these, 3989 participants were included in the intensive treatment group (mean [SD] age, 67.9 [9.2] years; 2570 [64.4%] men and 1419 [35.6%] women; 1212 [30.4%] non-Hispanic Black and 2777 [69.6%] non-Black participants) and 3929 were included in the standard treatment group (mean [SD] age, 67.9 [9.4] years; 2570 [65.4%] men and 1359 [34.6%] women; 1249 [31.8%] non-Hispanic Black and 2680 [68.2%] non-Black participants) (<xref rid="zoi230445t1" ref-type="table">Table 1</xref>). Participants in both the intensive and standard treatment groups had similar educational attainment, insurance coverage, medical history, and clinical and laboratory characteristics. Over a median follow up of 4.13 (IQR, 3.50-5.88) years, 765 participants in the intensive treatment group and 828 in the standard treatment group had probable dementia and amnestic MCI (<xref rid="zoi230445t2" ref-type="table">Table 2</xref>). In the highest tertile of estimated benefit using the full data set, a projected value of −0.027 translates to 27 events prevented per 1000 persons treated with intensive vs standard treatment over 4.13 years of follow-up. A total of 854 participants in the intensive treatment group and 954 in the standard treatment group had probable dementia, amnestic MCI, or death (eTable 3 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 1</xref>). Moreover, 256 participants in the intensive treatment group and 314 in the standard treatment group had probable dementia or died (eTable 4 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 1</xref>). Additionally, 482 participants in the intensive treatment group and 574 in the standard treatment group had probable dementia or protocol-defined MCI or died (eTable 5 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 1</xref>). The difference between observed and mean estimated risks within tertiles of estimated cognitive benefit were minimal for all outcomes. For example, the difference between the elastic-net Cox proportional hazards regression estimated risk and observed risk for the first estimated benefit tertile using the full set was −0.014. This minimal difference indicates that our estimation model was able to project our outcome very close to the observed risk. Additionally, the difference between our estimated and observed model was similar whether we used the full set, augmented reduced set, or basic reduced set. As such, we could use a reduced set with a smaller number of covariates and expect similar performance from our estimation model. This remained true across all outcomes and covariate sets (<xref rid="zoi230445t2" ref-type="table">Table 2</xref> and eTables 3-5 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
              <table-wrap position="float" id="zoi230445t1">
                <label>Table 1. </label>
                <caption>
                  <title>Baseline Characteristics of SPRINT Participants Included for Model Derivation</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="45.98%" span="1"/>
                  <col width="26.92%" span="1"/>
                  <col width="27.1%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Treatment group<xref rid="zoi230445t1n1" ref-type="table-fn"><sup>a</sup></xref></th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Intensive treatment (n = 3989)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard treatment (n = 3929)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.9 (9.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.9 (9.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Men</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2570 (64.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2570 (65.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Women</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1419 (35.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1359 (34.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race and ethnicity</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic Black</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1212 (30.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1249 (31.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Black<xref rid="zoi230445t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2777 (69.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2680 (68.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Social and behavioral</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lives with others</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2871 (72.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2806 (71.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Has private insurance</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1778 (44.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1656 (42.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current smoker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">519 (13.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">502 (12.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Former smoker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1719 (43.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1681 (42.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Never smoker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1751 (43.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1746 (44.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Employed</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">854 (21.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">850 (21.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Engages in vigorous physical activity (≥15 min/d)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2922 (73.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2912 (74.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Alcohol consumption, median No. of drinks/d (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Educational attainment</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Less than high school</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">338 (8.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">354 (9.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High school graduate only</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">658 (16.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">630 (16.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Post–high school graduate</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1418 (35.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1394 (35.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> College graduate or greater</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1575 (39.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1551 (39.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Health insurance status<xref rid="zoi230445t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Uninsured</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">410 (10.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">400 (10.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicare</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2176 (54.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2185 (55.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Medicaid</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">241 (6.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">259 (6.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Private</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1778 (44.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1656 (42.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> VA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">815 (20.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">785 (20.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Usual source of care</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Physicians’ office and/or outpatient clinic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3377 (84.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3348 (85.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Community health care facility or other</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">449 (11.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">430 (10.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No usual source of care</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">163 (4.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">151 (3.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medical history</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Clinical CVD</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">624 (15.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">602 (15.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Left ventricular hypertrophy</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">726 (18.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">722 (18.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Dizziness when standing</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">161 (4.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">161 (4.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of coronary revascularization</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">381 (9.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">361 (9.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> History of depression (self-report)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">714 (17.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">709 (18.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Baseline cognitive assessments</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Montreal Cognitive Assessment, median (IQR) score<xref rid="zoi230445t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">24 (21-26)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">23 (21-26)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Logical Memory form II, median (IQR) score<xref rid="zoi230445t1n5" ref-type="table-fn"><sup>e</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9 (6-11)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8 (6-11)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Digit Symbol Coding Test, median (IQR) score<xref rid="zoi230445t1n6" ref-type="table-fn"><sup>f</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">51 (42-61)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">51 (41-61)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Serial 7s, median (IQR) score<xref rid="zoi230445t1n7" ref-type="table-fn"><sup>g</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (2-3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (2-3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Clinical and laboratory measurements, median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Systolic BP, mm Hg</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">138 (129-149)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">139 (130-149)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Diastolic BP, mm Hg</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">78 (70-86)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">78 (70-86)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Resting heart rate, beats/min</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">65 (58-73)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">65 (58-74)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Serum potassium level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.2 (3.9-4.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.2 (3.9-4.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Serum creatinine level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.0 (0.9-1.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.0 (0.9-1.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Albumin to creatinine ratio, mg/g</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.5 (5.7-20.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.4 (5.6-21.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total cholesterol level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">187 (161-215)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">186 (161-214)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> HDL cholesterol level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">50 (43-60)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">50 (43-60)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Triglyceride level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">108 (77-150)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">107 (77-153)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> BMI</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">29.1 (26.0-33.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">29.1 (26.0-32.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Serum glucose level, mg/dL</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">97 (91-105)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">97 (91-105)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medication use</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Aspirin</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2144 (53.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2056 (52.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Statin</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1716 (43.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1769 (45.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> NSAID</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1557 (39.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1429 (36.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medication use</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Benzodiazepines</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">239 (6.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">221 (5.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Anticholinergics</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">386 (9.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">365 (9.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antidepressants</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">476 (11.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">475 (12.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. of nonantihypertensive medications, median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (1-5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3 (1-5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. of antihypertensive medications, median (IQR)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (1-3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (1-3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ARB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">851 (21.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">852 (21.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ACE-I</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1543 (38.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1440 (36.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> DHP CCB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1187 (29.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1197 (30.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-DHP CCB</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">207 (5.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">225 (5.7)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Thiazide diuretic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1585 (39.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1628 (41.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Loop diuretic</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">225 (5.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">213 (5.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> β-Blocker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1528 (38.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1372 (34.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> α-Blocker</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">403 (10.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">396 (10.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other antihypertensive medication</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">387 (9.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">414 (10.5)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; CCB, calcium channel blocker; CVD, cardiovascular disease; DHP, dihydropyridine; HDL, high-density lipoprotein; NSAID, nonsteroidal anti-inflammatory drug; VA, Department of Veterans Affairs.</p>
                  <p>SI conversion factors: To convert potassium to mmol/L, multiply by 1.0; to convert creatinine to μmol/L, multiply by 88.4; to convert total cholesterol to mmol/L, multiply by 0.0259; to convert HDL cholesterol to mmol/L, multiply by 0.0259; to convert triglycerides to mmol/L, multiply by 0.0113; to convert serum glucose to mmol/L, multiply by 0.0555.</p>
                  <fn id="zoi230445t1n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Unless otherwise indicated, data are expressed as No. (%) of participants.</p>
                  </fn>
                  <fn id="zoi230445t1n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Includes Hispanic, non-Hispanic White, and other (American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and other race or ethnicity).</p>
                  </fn>
                  <fn id="zoi230445t1n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Participants were able to choose to more than 1 category.</p>
                  </fn>
                  <fn id="zoi230445t1n4">
                    <label>
                      <sup>d</sup>
                    </label>
                    <p>Scores range from 0 to 30, with higher scores denoting better cognitive function. Subtest of the Wechsler Memory Scale.</p>
                  </fn>
                  <fn id="zoi230445t1n5">
                    <label>
                      <sup>e</sup>
                    </label>
                    <p>Scores range from 0 to 14, with higher scores denoting better cognitive function. Subtest of the Wechsler Adult Intelligence Scale.</p>
                  </fn>
                  <fn id="zoi230445t1n6">
                    <label>
                      <sup>f</sup>
                    </label>
                    <p>Scores range from 0 to 135, with higher scores denoting better cognitive function.</p>
                  </fn>
                  <fn id="zoi230445t1n7">
                    <label>
                      <sup>g</sup>
                    </label>
                    <p>Scores range from 1 to 5, with higher scores indicating better cognitive function.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="zoi230445t2">
                <label>Table 2. </label>
                <caption>
                  <title>Observed Risks and Estimated and Observed Risk Differences With Intensive vs Standard Blood Pressure Control by Tertiles of Estimated Benefit in SPRINT for Primary Outcome<xref rid="zoi230445t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="18.14%" span="1"/>
                  <col width="10.75%" span="1"/>
                  <col width="9.22%" span="1"/>
                  <col width="9.47%" span="1"/>
                  <col width="10.39%" span="1"/>
                  <col width="10.47%" span="1"/>
                  <col width="18.82%" span="1"/>
                  <col width="12.74%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Estimated benefit tertile</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. of SPRINT participants</th>
                      <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Primary outcome events, No. (%)</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Absolute risk difference, intensive vs standard treatment group</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Intensive (n = 3989)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard (n = 3929)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Intensive (n = 3989)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Standard (n = 3929)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Estimated (median)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Observed (95% CI)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Difference between observed and estimated</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td colspan="8" valign="top" align="left" scope="col" rowspan="1">
                        <bold>Full set</bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">High (−0.0504 to −0.0159)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1329</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1310</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">513 (38.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">526 (40.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.027</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.013 (−0.054 to 0.028)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.014</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Medium (−0.0159 to −0.00552)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1326</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1313</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">181 (13.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">221 (16.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.010</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.032 (−0.06 to −0.003)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.022</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Low (−0.00552 to 0.000292)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1334</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1305</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">71 (5.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">81 (6.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.003</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.008 (−0.025 to 0.010)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.005</td>
                    </tr>
                    <tr>
                      <td colspan="8" valign="top" align="left" scope="col" rowspan="1">
                        <bold>Augmented reduced set<xref rid="zoi230445t2n2" ref-type="table-fn"><sup>b</sup></xref></bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">High (−0.0512 to −0.0148)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1330</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1317</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">501 (37.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">526 (39.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.027</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.006 (−0.047 to 0.034)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.02</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Medium (−0.0148 to −0.00599)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1331</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1315</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">185 (13.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">215 (16.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.010</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.038 (−0.067 to −0.010)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.028</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Low (−0.00599 to 0.00236)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1336</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1311</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">80 (6.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">91 (6.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.003</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.007 (−0.026 to 0.011)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.004</td>
                    </tr>
                    <tr>
                      <td colspan="8" valign="top" align="left" scope="col" rowspan="1">
                        <bold>Basic reduced set<xref rid="zoi230445t2n3" ref-type="table-fn"><sup>c</sup></xref></bold>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">High (−0.0398 to −0.0194)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1338</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1306</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">423 (31.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">475 (36.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.026</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.041 (−0.08 to −0.002)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.015</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Medium (−0.0194 to −0.0112)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1305</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1339</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">219 (16.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">225 (16.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.015</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.002 (−0.032 to 0.028)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.014</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Low (−0.0112 to 0.0024)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1351</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1293</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">124 (9.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">131 (10.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.007</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.012 (−0.035 to 0.01)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.005</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviation: SPRINT, Systolic Blood Pressure Intervention Trial.</p>
                  <fn id="zoi230445t2n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Primary outcome consists of probable dementia or amnestic mild cognitive impairment. Findings are derived from modified elastic-net Cox proportional hazards regression.</p>
                  </fn>
                  <fn id="zoi230445t2n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Includes most influential covariates based on prior knowledge regardless of whether they are readily available at the point of care.</p>
                  </fn>
                  <fn id="zoi230445t2n3">
                    <label>
                      <sup>c</sup>
                    </label>
                    <p>Includes most influential covariates that are routinely available at point of care and/or can be easily obtained.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="H2-7-ZOI230445">
                <title>Estimated Absolute Risks of Each Outcome</title>
                <p>The modified elastic-net Cox proportional hazards regression models estimating each of the outcomes using the full set performed well based on the C statistic, GND test, and MAE for the primary outcome of probable dementia and amnestic MCI (C statistic = 0.79; GND <italic>P</italic> = .23; MAE = 0.009); probable dementia, amnestic MCI, and death (C statistic = 0.79; GND <italic>P</italic> = .24; MAE = 0.011); probable dementia and death (C statistic = 0.82; GND <italic>P</italic> = .49; MAE = 0.007); and the composite of probable dementia, protocol-defined MCI, and death (C statistic = 0.81; GND <italic>P</italic> = .98; MAE = 0.003) (<xref rid="zoi230445f2" ref-type="fig">Figure 2</xref> and eTable 6 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). Moreover, the modified elastic-net Cox proportional hazards models to estimate outcomes performed well with the reduced set and the basic reduced set (eFigures 2 and 3 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                <fig position="float" id="zoi230445f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Observed Absolute Risks Within Deciles of Estimated Risk at 4.13 Years of Follow-up for the Primary Cognitive Outcome</title>
                    <p>Calibration plots display the association between average risk estimated by elastic-net Cox proportional hazards regression model and observed risk estimated by Kaplan-Meier at 4.13 years for participants separated by decile of estimated risk. The solid blue diagonal lines show a perfect expected risk vs observed risk slope of 1. The points and whiskers present the observed absolute risk and 95% CIs across deciles of overall estimated risk. Calibration assesses how well elastic-net Cox proportional hazards regression model–estimated primary cognitive outcome event rates correspond to observed rates. A formal test of calibration was performed using the Greenwood-Nam-D'Agostino test. aMCI indicates amnestic mild cognitive impairment; PD, probable dementia.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2314443-g002" position="float"/>
                </fig>
                <p>eFigure 4 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref> shows the strength of each bivariate association for each covariate with the relevant outcome expressed as the standardized univariate HR. The baseline factors that were associated with higher risk for probable dementia and protocol-defined MCI were older age (HR per 1 SD, 1.87 [95% CI, 1.78-1.96]), being enrolled in Medicare (HR per 1 SD, 1.42 [95% CI, 1.35-1.49]), receiving insurance benefits through the Veterans Health Administration (HR per 1 SD, 1.15 [95% CI, 1.10-1.20]), and higher baseline serum creatinine level (HR per 1 SD, 1.24 [95% CI, 1.19-1.29]). Higher baseline cognitive assessment performance as measured with Montreal Cognitive Assessment, Logical Memory forms, serial 7s, and Digit Symbol Coding Test (HR per 1 SD, 0.43 [95% CI, 0.41-0.44]) and being employed (HR per 1 SD, 0.44 [95% CI, 0.42-0.46]) were associated with a lower risk of probable dementia or amnestic MCI. The patterns of associations were similar for the composites of probable dementia, amnestic MCI, or death and probable dementia and death as well as the composite of probable dementia, protocol-defined MCI, or death.</p>
              </sec>
              <sec id="H2-8-ZOI230445">
                <title>Estimated Magnitude of Benefit With Intensive vs Standard Treatment</title>
                <p>Risk magnification plots (<xref rid="zoi230445f3" ref-type="fig">Figure 3</xref>) show the association between the estimated treatment benefit (expressed as differences in risk between the treatment groups) and the estimated baseline risk for each cognitive outcome and for each feature set, separately. The models using the full covariate set are shown in <xref rid="zoi230445f3" ref-type="fig">Figure 3</xref>; those using the augmented reduced and basic reduced covariate sets are shown in eFigures 5 and 6 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>. For the full covariate set, the risk amplification was approximately linear for the primary outcome of probable dementia and amnestic MCI (<italic>P</italic> = .69 for linearity). However, the association between baseline risk and effect of intensive vs standard SBP treatment on probable dementia or amnestic MCI; on probable dementia, amnestic MCI, or death; and on probable dementia or death tended to flatten at the highest level of baseline risk, with wide 95% CIs indicating substantial uncertainty. The risk amplification was approximately linear for the outcome of probable dementia or amnestic MCI or death using the full covariate set (<italic>P</italic> = .86 for linearity), augmented reduced set (<italic>P</italic> = .18 for linearity), and for the basic reduced set (<italic>P</italic> = .13 for linearity), with the association tending to flatten or even increase slightly, suggesting a less beneficial effect of the treatment at higher levels of baseline risk. The wide 95% CIs at high baseline risk reflect higher uncertainty in estimating the association between absolute risk and the risk difference at higher levels of baseline risk (eFigures 5 and 6 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                <fig position="float" id="zoi230445f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Estimated Magnitude of Benefit With Intensive vs Standard Systolic Blood Pressure Treatment Across a Range of Estimated Baseline Risk</title>
                    <p>Solid orange lines represent direct risk magnification, where the absolute risk reduction is directly proportional to the baseline risk assuming a constant relative treatment effect on the hazard ratio scale. Solid blue lines represent the association between average elastic-net Cox proportional hazards regression model–estimated absolute risk difference for each outcome across the full range of baseline risk. The shaded gray areas represent the 95% CIs for the estimated risk difference. The histogram represents the distribution of baseline risk of each outcome in the Systolic Blood Pressure Intervention Trial population used in the current analysis. The blue circles represent the average observed risk difference for each outcome within quartiles of the Cox proportional hazards regression model–estimated absolute risk difference. The bars represent 95% CIs of the observed risk differences. aMCI indicates amnestic mild cognitive impairment; PD, probable dementia.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e2314443-g003" position="float"/>
                </fig>
                <p>The results of the hybrid risk- and effect-modeling analyses revealed that discrimination was not substantially improved from the full set, augmented reduced set, or basic reduced set in the primary analysis (eTable 6 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). Thus, it does not appear that estimation of the overall risk of our outcomes can be substantially improved by adding the interaction terms (treatment with each of age, sex, race, baseline MCI, and baseline CVD diagnosis subgroups).</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI230445">
              <title>Discussion</title>
              <p>Identifying baseline characteristics that project a higher magnitude of benefit within a clinical trial population is challenging yet important to advance personalized medicine.<sup><xref rid="zoi230445r5" ref-type="bibr">5</xref>,<xref rid="zoi230445r33" ref-type="bibr">33</xref>,<xref rid="zoi230445r34" ref-type="bibr">34</xref>,<xref rid="zoi230445r35" ref-type="bibr">35</xref></sup> In this estimation modeling analysis of adjudicated cognitive outcomes in SPRINT, we found that higher baseline estimated risk of amnestic MCI or probable dementia was associated with greater absolute benefit from intensive (&lt;120 mm Hg) compared with standard (&lt;140 mm Hg) SBP treatment (<xref rid="zoi230445f3" ref-type="fig">Figure 3</xref>). These findings were consistent across all 3 covariate sets and after death was added to the composite outcome. We also found that the estimation ability of our models for amnestic MCI or probable dementia was not substantially reduced when using the augmented or basic covariate set, suggesting that simpler models perform similarly and may be preferred for implementation (eFigure 5 and 6 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). We found the strongest estimation factors for amnestic MCI or probable dementia were age, insurance status, kidney function, cognitive test results, and educational level (eFigure 2 in <xref rid="note-ZOI230445-1-s" ref-type="supplementary-material">Supplement 2</xref>). Our results highlight the importance of prioritizing hypertension management of patients at increased risk of cognitive outcomes for intensive SBP treatment and are contrary to the belief of many that hypertension therapy is often limited value in older patients compared with middle-aged patients.</p>
              <p>Hypertension is an important modifiable risk factor for CVD and dementia.<sup><xref rid="zoi230445r36" ref-type="bibr">36</xref>,<xref rid="zoi230445r37" ref-type="bibr">37</xref>,<xref rid="zoi230445r38" ref-type="bibr">38</xref></sup> Several cohort studies show that hypertension (SBP ≥140 mm Hg and SBP ≥130 mm Hg) is associated with higher risk of dementia.<sup><xref rid="zoi230445r38" ref-type="bibr">38</xref>,<xref rid="zoi230445r39" ref-type="bibr">39</xref>,<xref rid="zoi230445r40" ref-type="bibr">40</xref></sup> Additionally, a recent meta-analysis of 6 community-based prospective studies<sup><xref rid="zoi230445r37" ref-type="bibr">37</xref></sup> showed that antihypertensive medication use reduces the risk of dementia in patients with SBP of 140 mm Hg or higher or diastolic BP of 90 mm Hg or higher. These results are consistent with the SPRINT findings in which intensive SBP treatment significantly reduced the risk of a composite outcome of MCI or probable dementia (HR, 0.85 [95% CI, 0.74-0.97]).<sup><xref rid="zoi230445r1" ref-type="bibr">1</xref></sup> However, the double randomized Heart Outcomes Prevention Evaluation–3 Study<sup><xref rid="zoi230445r41" ref-type="bibr">41</xref></sup> showed that for older patients with intermediate cardiovascular risk with no prior CVD, long-term SBP lowering (median follow-up, 5.7 years) with candesartan cilexetil and hydrochlorothiazide did not affect cognitive or functional decline using a very limited cognitive battery insufficient to ascertain MCI or dementia. While some clinicians postulate that intensive BP control is too burdensome, SPRINT found that an average of only 1 additional medication is needed to achieve an SBP of less than 120 mm Hg, and serious adverse effects were not increased.<sup><xref rid="zoi230445r13" ref-type="bibr">13</xref></sup> Our results indicate that being older, having high serum creatinine levels, being enrolled in Medicare or Veterans Health Administration insurance, and having low baseline cognitive function most affected the association between intensive BP reduction and cognitive outcomes. These patients would benefit most from treatment intensification and should be targeted specifically for risk reduction. Additionally, we did not find evidence of effect modification on the relative hazard scale for prespecified subgroups (age, sex, race, baseline MCI [not adjudicated], and CVD diagnosis at baseline).</p>
              <p>Overall, greater cognitive benefit was observed with intensive BP treatment in patients at greater risk of cognitive decline at baseline (<xref rid="zoi230445f3" ref-type="fig">Figure 3</xref>). Similar findings have been shown in other SPRINT outcomes, in which the greater the baseline CVD risk, the greater the CVD benefit of intensive SBP treatment.<sup><xref rid="zoi230445r3" ref-type="bibr">3</xref></sup> These data further support recommending intensive SBP treatment for patients who fulfill SPRINT eligibility criteria and have high estimated risk of CVD events or cognitive decline. Moreover, previous studies have shown that there is no increased risk for overall adverse effects by intensive treatment in SPRINT and that participants with the highest estimated CVD benefit from intensive treatment, and that although they are more likely to experience treatment-related adverse events, these were mild and transient.<sup><xref rid="zoi230445r2" ref-type="bibr">2</xref>,<xref rid="zoi230445r3" ref-type="bibr">3</xref></sup> By maintaining cognitive function and avoiding CVD events, events that contributed significantly to loss of independence, duration and quality of life could be improved.<sup><xref rid="zoi230445r4" ref-type="bibr">4</xref></sup> This could be achieved with intensive BP control and is important to achieve as the population ages. In fact, over 12 million US adults are eligible to initiate or intensify antihypertensive treatment, and targeting populations based on baseline risk might be adventitious in limited resource settings.<sup><xref rid="zoi230445r42" ref-type="bibr">42</xref></sup></p>
              <sec id="H2-9-ZOI230445">
                <title>Strengths and Limitations</title>
                <p>These results should be interpreted within the context of the following strengths and limitations. Strengths include the use of complete SPRINT data and a randomized design. Additionally, cognitive outcomes were adjudicated by clinical experts in the care of persons with cognitive impairment and classified into meaningful clinical categories (no impairment, MCI, and probable dementia). Although we observed evidence of risk magnification, greater absolute risk reduction among patients with higher baseline risk of cognitive outcomes, the 95% CIs were wide among participants with high estimated absolute risk or an inverse association was observed due to small sample size (<xref rid="zoi230445f3" ref-type="fig">Figure 3</xref>). Given the limited existence of validated risk estimation models for cognitive impairment and dementia, we developed an internal risk model that we include in this report, and results may differ with external validation in other data sets or populations. We used several risk models based on covariates available in the clinical setting, although it is possible that we did not include a clinically informative variable if it was unmeasured in the SPRINT data (eg, family history of cognitive decline). Finally, we did not weigh the absolute benefits of intensive treatment on cognitive decline against the potential absolute harms (eg, serious adverse events) with intensive treatment.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI230445">
              <title>Conclusions</title>
              <p>This secondary analysis of the SPRINT randomized clinical trial found that participants with higher baseline risk of MCI or dementia gained the greatest absolute benefit from intensive SBP treatment. The baseline clinical factors associated with risk of MCI or dementia include older age, worse kidney function, being enrolled in Medicare or Veterans Health Administration insurance, lower educational attainment, and low baseline cognitive function. If we are to prioritize intensifying antihypertensive treatment based on cognitive benefit, especially among patients who lack equitable access to health care and in resource-poor settings, we would recommend targeting patients at high risk of cognitive impairment initially. However, we had limited ability in identifying benefit in patients with high cognitive risk at baseline due to limited sample size.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI230445">
              <title>References</title>
              <ref id="zoi230445r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Pajewski</surname><given-names>NM</given-names></string-name>, <string-name><surname>Auchus</surname><given-names>AP</given-names></string-name>, <etal/>; <collab>SPRINT MIND Investigators for the SPRINT Research Group</collab></person-group>. <article-title>Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2019</year>;<volume>321</volume>(<issue>6</issue>):<fpage>553</fpage>-<lpage>561</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2018.21442</pub-id><?supplied-pmid 30688979?><pub-id pub-id-type="pmid">30688979</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Whelton</surname><given-names>PK</given-names></string-name>, <etal/>; <collab>SPRINT Research Group</collab></person-group>. <article-title>A randomized trial of intensive versus standard blood-pressure control</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>22</issue>):<fpage>2103</fpage>-<lpage>2116</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1511939</pub-id><?supplied-pmid 26551272?><pub-id pub-id-type="pmid">26551272</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bress</surname><given-names>AP</given-names></string-name>, <string-name><surname>Greene</surname><given-names>T</given-names></string-name>, <string-name><surname>Derington</surname><given-names>CG</given-names></string-name>, <etal/>; <collab>SPRINT Research Group</collab></person-group>. <article-title>Patient selection for intensive blood pressure management based on benefit and adverse events</article-title>. <source>J Am Coll Cardiol</source>. <year>2021</year>;<volume>77</volume>(<issue>16</issue>):<fpage>1977</fpage>-<lpage>1990</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jacc.2021.02.058</pub-id><?supplied-pmid 33888247?><pub-id pub-id-type="pmid">33888247</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bress</surname><given-names>AP</given-names></string-name>, <string-name><surname>Bellows</surname><given-names>BK</given-names></string-name>, <string-name><surname>King</surname><given-names>JB</given-names></string-name>, <etal/>; <collab>SPRINT Research Group</collab></person-group>. <article-title>Cost-effectiveness of intensive versus standard blood-pressure control</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>8</issue>):<fpage>745</fpage>-<lpage>755</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMsa1616035</pub-id><?supplied-pmid 28834469?><pub-id pub-id-type="pmid">28834469</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kent</surname><given-names>DM</given-names></string-name>, <string-name><surname>van Klaveren</surname><given-names>D</given-names></string-name>, <string-name><surname>Paulus</surname><given-names>JK</given-names></string-name>, <etal/></person-group>. <article-title>The Predictive Approaches to Treatment Effect Heterogeneity (PATH) statement: explanation and elaboration</article-title>. <source>Ann Intern Med</source>. <year>2020</year>;<volume>172</volume>(<issue>1</issue>):<fpage>W1</fpage>-<lpage>W25</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M18-3668</pub-id><?supplied-pmid 31711094?><pub-id pub-id-type="pmid">31711094</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ambrosius</surname><given-names>WT</given-names></string-name>, <string-name><surname>Sink</surname><given-names>KM</given-names></string-name>, <string-name><surname>Foy</surname><given-names>CG</given-names></string-name>, <etal/>; <collab>SPRINT Study Research Group</collab></person-group>. <article-title>The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)</article-title>. <source>Clin Trials</source>. <year>2014</year>;<volume>11</volume>(<issue>5</issue>):<fpage>532</fpage>-<lpage>546</lpage>. doi:<pub-id pub-id-type="doi">10.1177/1740774514537404</pub-id><?supplied-pmid 24902920?><pub-id pub-id-type="pmid">24902920</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nasreddine</surname><given-names>ZS</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>NA</given-names></string-name>, <string-name><surname>Bédirian</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source>. <year>2005</year>;<volume>53</volume>(<issue>4</issue>):<fpage>695</fpage>-<lpage>699</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53221.x</pub-id><?supplied-pmid 15817019?><pub-id pub-id-type="pmid">15817019</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r8">
                <label>8</label>
                <mixed-citation publication-type="webpage">Wechsler D. Wechsler Adult Intelligence Scale. 4th ed. 2008. Accessed February 21, 2023. <ext-link xlink:href="https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Cognition-&amp;-Neuro/Wechsler-Adult-Intelligence-Scale-%7C-Fourth-Edition/p/100000392.html" ext-link-type="uri">https://www.pearsonassessments.com/store/usassessments/en/Store/Professional-Assessments/Cognition-%26-Neuro/Wechsler-Adult-Intelligence-Scale-%7C-Fourth-Edition/p/100000392.html</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230445r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pfeffer</surname><given-names>RI</given-names></string-name>, <string-name><surname>Kurosaki</surname><given-names>TT</given-names></string-name>, <string-name><surname>Harrah</surname><given-names>CH</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Chance</surname><given-names>JM</given-names></string-name>, <string-name><surname>Filos</surname><given-names>S</given-names></string-name></person-group>. <article-title>Measurement of functional activities in older adults in the community</article-title>. <source>J Gerontol</source>. <year>1982</year>;<volume>37</volume>(<issue>3</issue>):<fpage>323</fpage>-<lpage>329</lpage>. doi:<pub-id pub-id-type="doi">10.1093/geronj/37.3.323</pub-id><?supplied-pmid 7069156?><pub-id pub-id-type="pmid">7069156</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gaussoin</surname><given-names>SA</given-names></string-name>, <string-name><surname>Espeland</surname><given-names>MA</given-names></string-name>, <string-name><surname>Absher</surname><given-names>J</given-names></string-name>, <string-name><surname>Howard</surname><given-names>BV</given-names></string-name>, <string-name><surname>Jones</surname><given-names>BM</given-names></string-name>, <string-name><surname>Rapp</surname><given-names>SR</given-names></string-name></person-group>. <article-title>Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the Women’s Health Initiative Memory Study supplemental case ascertainment protocol</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2012</year>;<volume>27</volume>(<issue>2</issue>):<fpage>205</fpage>-<lpage>214</lpage>. doi:<pub-id pub-id-type="doi">10.1002/gps.2714</pub-id><?supplied-pmid 21416508?><pub-id pub-id-type="pmid">21416508</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Welsh</surname><given-names>KA</given-names></string-name>, <string-name><surname>Breitner</surname><given-names>JCS</given-names></string-name>, <string-name><surname>Magruder-Habib</surname><given-names>KM</given-names></string-name></person-group>. <article-title>Detection of dementia in the elderly using telephone screening of cognitive status</article-title>. <source>Cogn Behav Neurol</source>. <year>1993</year>;<volume>6</volume>:<fpage>103</fpage>-<lpage>110</lpage>.</mixed-citation>
              </ref>
              <ref id="zoi230445r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kawas</surname><given-names>C</given-names></string-name>, <string-name><surname>Segal</surname><given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>WF</given-names></string-name>, <string-name><surname>Corrada</surname><given-names>M</given-names></string-name>, <string-name><surname>Thal</surname><given-names>LJ</given-names></string-name></person-group>. <article-title>A validation study of the Dementia Questionnaire</article-title>. <source>Arch Neurol</source>. <year>1994</year>;<volume>51</volume>(<issue>9</issue>):<fpage>901</fpage>-<lpage>906</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.1994.00540210073015</pub-id><?supplied-pmid 8080390?><pub-id pub-id-type="pmid">8080390</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Berlowitz</surname><given-names>DR</given-names></string-name>, <string-name><surname>Foy</surname><given-names>CG</given-names></string-name>, <string-name><surname>Kazis</surname><given-names>LE</given-names></string-name>, <etal/>; <collab>SPRINT Research Group</collab></person-group>. <article-title>Effect of intensive blood-pressure treatment on patient-reported outcomes</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>8</issue>):<fpage>733</fpage>-<lpage>744</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1611179</pub-id><?supplied-pmid 28834483?><pub-id pub-id-type="pmid">28834483</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Campbell</surname><given-names>NL</given-names></string-name>, <string-name><surname>Unverzagt</surname><given-names>F</given-names></string-name>, <string-name><surname>LaMantia</surname><given-names>MA</given-names></string-name>, <string-name><surname>Khan</surname><given-names>BA</given-names></string-name>, <string-name><surname>Boustani</surname><given-names>MA</given-names></string-name></person-group>. <article-title>Risk factors for the progression of mild cognitive impairment to dementia</article-title>. <source>Clin Geriatr Med</source>. <year>2013</year>;<volume>29</volume>(<issue>4</issue>):<fpage>873</fpage>-<lpage>893</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cger.2013.07.009</pub-id><?supplied-pmid 24094301?><pub-id pub-id-type="pmid">24094301</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McKhann</surname><given-names>GM</given-names></string-name>, <string-name><surname>Knopman</surname><given-names>DS</given-names></string-name>, <string-name><surname>Chertkow</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>263</fpage>-<lpage>269</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id><?supplied-pmid 21514250?><pub-id pub-id-type="pmid">21514250</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Albert</surname><given-names>MS</given-names></string-name>, <string-name><surname>DeKosky</surname><given-names>ST</given-names></string-name>, <string-name><surname>Dickson</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title>. <source>Alzheimers Dement</source>. <year>2011</year>;<volume>7</volume>(<issue>3</issue>):<fpage>270</fpage>-<lpage>279</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.008</pub-id><?supplied-pmid 21514249?><pub-id pub-id-type="pmid">21514249</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pankratz</surname><given-names>VS</given-names></string-name>, <string-name><surname>Roberts</surname><given-names>RO</given-names></string-name>, <string-name><surname>Mielke</surname><given-names>MM</given-names></string-name>, <etal/></person-group>. <article-title>Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging</article-title>. <source>Neurology</source>. <year>2015</year>;<volume>84</volume>(<issue>14</issue>):<fpage>1433</fpage>-<lpage>1442</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000001437</pub-id><?supplied-pmid 25788555?><pub-id pub-id-type="pmid">25788555</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Niu</surname><given-names>H</given-names></string-name>, <string-name><surname>Álvarez-Álvarez</surname><given-names>I</given-names></string-name>, <string-name><surname>Guillén-Grima</surname><given-names>F</given-names></string-name>, <string-name><surname>Aguinaga-Ontoso</surname><given-names>I</given-names></string-name></person-group>. <article-title>Prevalence and incidence of Alzheimer’s disease in Europe: a meta-analysis</article-title>. <source>Neurologia</source>. <year>2017</year>;<volume>32</volume>(<issue>8</issue>):<fpage>523</fpage>-<lpage>532</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.nrl.2016.02.016</pub-id><?supplied-pmid 27130306?><pub-id pub-id-type="pmid">27130306</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Carone</surname><given-names>M</given-names></string-name>, <string-name><surname>Asgharian</surname><given-names>M</given-names></string-name>, <string-name><surname>Jewell</surname><given-names>NP</given-names></string-name></person-group>. <article-title>Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data</article-title>. <source>J Am Stat Assoc</source>. <year>2014</year>;<volume>109</volume>(<issue>505</issue>):<fpage>24</fpage>-<lpage>35</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01621459.2013.859076</pub-id><?supplied-pmid 26139951?><pub-id pub-id-type="pmid">26139951</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Stern</surname><given-names>Y</given-names></string-name>, <string-name><surname>Gurland</surname><given-names>B</given-names></string-name>, <string-name><surname>Tatemichi</surname><given-names>TK</given-names></string-name>, <string-name><surname>Tang</surname><given-names>MX</given-names></string-name>, <string-name><surname>Wilder</surname><given-names>D</given-names></string-name>, <string-name><surname>Mayeux</surname><given-names>R</given-names></string-name></person-group>. <article-title>Influence of education and occupation on the incidence of Alzheimer’s disease</article-title>. <source>JAMA</source>. <year>1994</year>;<volume>271</volume>(<issue>13</issue>):<fpage>1004</fpage>-<lpage>1010</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1994.03510370056032</pub-id><?supplied-pmid 8139057?><pub-id pub-id-type="pmid">8139057</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Evans</surname><given-names>DA</given-names></string-name>, <string-name><surname>Hebert</surname><given-names>LE</given-names></string-name>, <string-name><surname>Beckett</surname><given-names>LA</given-names></string-name>, <etal/></person-group>. <article-title>Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons</article-title>. <source>Arch Neurol</source>. <year>1997</year>;<volume>54</volume>(<issue>11</issue>):<fpage>1399</fpage>-<lpage>1405</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.1997.00550230066019</pub-id><?supplied-pmid 9362989?><pub-id pub-id-type="pmid">9362989</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Prince</surname><given-names>M</given-names></string-name>, <string-name><surname>Acosta</surname><given-names>D</given-names></string-name>, <string-name><surname>Ferri</surname><given-names>CP</given-names></string-name>, <etal/></person-group>. <article-title>Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study</article-title>. <source>Lancet</source>. <year>2012</year>;<volume>380</volume>(<issue>9836</issue>):<fpage>50</fpage>-<lpage>58</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(12)60399-7</pub-id><?supplied-pmid 22626851?><pub-id pub-id-type="pmid">22626851</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ngandu</surname><given-names>T</given-names></string-name>, <string-name><surname>von Strauss</surname><given-names>E</given-names></string-name>, <string-name><surname>Helkala</surname><given-names>EL</given-names></string-name>, <etal/></person-group>. <article-title>Education and dementia: what lies behind the association?</article-title><source>Neurology</source>. <year>2007</year>;<volume>69</volume>(<issue>14</issue>):<fpage>1442</fpage>-<lpage>1450</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000277456.29440.16</pub-id><?supplied-pmid 17909157?><pub-id pub-id-type="pmid">17909157</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fotenos</surname><given-names>AF</given-names></string-name>, <string-name><surname>Mintun</surname><given-names>MA</given-names></string-name>, <string-name><surname>Snyder</surname><given-names>AZ</given-names></string-name>, <string-name><surname>Morris</surname><given-names>JC</given-names></string-name>, <string-name><surname>Buckner</surname><given-names>RL</given-names></string-name></person-group>. <article-title>Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>1</issue>):<fpage>113</fpage>-<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneurol.2007.27</pub-id><?supplied-pmid 18195148?><pub-id pub-id-type="pmid">18195148</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Petersen</surname><given-names>RC</given-names></string-name>, <string-name><surname>Smith</surname><given-names>GE</given-names></string-name>, <string-name><surname>Waring</surname><given-names>SC</given-names></string-name>, <string-name><surname>Ivnik</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Tangalos</surname><given-names>EG</given-names></string-name>, <string-name><surname>Kokmen</surname><given-names>E</given-names></string-name></person-group>. <article-title>Mild cognitive impairment: clinical characterization and outcome</article-title>. <source>Arch Neurol</source>. <year>1999</year>;<volume>56</volume>(<issue>3</issue>):<fpage>303</fpage>-<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneur.56.3.303</pub-id><?supplied-pmid 10190820?><pub-id pub-id-type="pmid">10190820</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name><surname>Sommerlad</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Dementia prevention, intervention, and care: 2020 report of the <italic>Lancet</italic> Commission</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>396</volume>(<issue>10248</issue>):<fpage>413</fpage>-<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30367-6</pub-id><?supplied-pmid 32738937?><pub-id pub-id-type="pmid">32738937</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fleurence</surname><given-names>RL</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>LH</given-names></string-name>, <string-name><surname>Califf</surname><given-names>RM</given-names></string-name>, <string-name><surname>Platt</surname><given-names>R</given-names></string-name>, <string-name><surname>Selby</surname><given-names>JV</given-names></string-name>, <string-name><surname>Brown</surname><given-names>JS</given-names></string-name></person-group>. <article-title>Launching PCORnet, a national patient-centered clinical research network</article-title>. <source>J Am Med Inform Assoc</source>. <year>2014</year>;<volume>21</volume>(<issue>4</issue>):<fpage>578</fpage>-<lpage>582</lpage>. doi:<pub-id pub-id-type="doi">10.1136/amiajnl-2014-002747</pub-id><?supplied-pmid 24821743?><pub-id pub-id-type="pmid">24821743</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zou</surname><given-names>H</given-names></string-name>, <string-name><surname>Hastie</surname><given-names>T</given-names></string-name></person-group>. <article-title>Regularization and variable selection via the elastic net</article-title>. <source>J Roy Stat Soc B</source>. <year>2005</year>;<volume>67</volume>(<issue>2</issue>):<fpage>301</fpage>-<lpage>320</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1467-9868.2005.00503.x</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Uno</surname><given-names>H</given-names></string-name>, <string-name><surname>Cai</surname><given-names>T</given-names></string-name>, <string-name><surname>Pencina</surname><given-names>MJ</given-names></string-name>, <string-name><surname>D’Agostino</surname><given-names>RB</given-names></string-name>, <string-name><surname>Wei</surname><given-names>LJ</given-names></string-name></person-group>. <article-title>On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1105</fpage>-<lpage>1117</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.4154</pub-id><?supplied-pmid 21484848?><pub-id pub-id-type="pmid">21484848</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r30">
                <label>30</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>D’Agostino</surname><given-names>RB</given-names></string-name>, <string-name><surname>Nam</surname><given-names>BH</given-names></string-name></person-group>. <part-title>Evaluation of the performance of survival analysis models: discrimination and calibration measures</part-title>. In: <person-group><string-name><surname>Balakrishnan</surname><given-names>N</given-names></string-name>, <string-name><surname>Rao</surname><given-names>CR</given-names></string-name></person-group>, eds. <source>Handbook of Statistics 23: Advances in Survival Analysis</source>. <publisher-name>Elsevier</publisher-name>; <year>2003</year>:<fpage>1</fpage>-<lpage>25</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0169-7161(03)23001-7</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Demler</surname><given-names>OV</given-names></string-name>, <string-name><surname>Paynter</surname><given-names>NP</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name></person-group>. <article-title>Tests of calibration and goodness-of-fit in the survival setting</article-title>. <source>Stat Med</source>. <year>2015</year>;<volume>34</volume>(<issue>10</issue>):<fpage>1659</fpage>-<lpage>1680</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.6428</pub-id><?supplied-pmid 25684707?><pub-id pub-id-type="pmid">25684707</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r32">
                <label>32</label>
                <mixed-citation publication-type="webpage">SprintCognitive. <year>2023</year>. Accessed October 30, 2021. <ext-link xlink:href="https://github.com/JianYingUT/SprintCognitive-.git" ext-link-type="uri">https://github.com/JianYingUT/SprintCognitive</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230445r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Brookes</surname><given-names>ST</given-names></string-name>, <string-name><surname>Whitely</surname><given-names>E</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Smith</surname><given-names>GD</given-names></string-name>, <string-name><surname>Mulheran</surname><given-names>PA</given-names></string-name>, <string-name><surname>Peters</surname><given-names>TJ</given-names></string-name></person-group>. <article-title>Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test</article-title>. <source>J Clin Epidemiol</source>. <year>2004</year>;<volume>57</volume>(<issue>3</issue>):<fpage>229</fpage>-<lpage>236</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.08.009</pub-id><?supplied-pmid 15066682?><pub-id pub-id-type="pmid">15066682</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dahabreh</surname><given-names>IJ</given-names></string-name>, <string-name><surname>Hayward</surname><given-names>R</given-names></string-name>, <string-name><surname>Kent</surname><given-names>DM</given-names></string-name></person-group>. <article-title>Using group data to treat individuals: understanding heterogeneous treatment effects in the age of precision medicine and patient-centred evidence</article-title>. <source>Int J Epidemiol</source>. <year>2016</year>;<volume>45</volume>(<issue>6</issue>):<fpage>2184</fpage>-<lpage>2193</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ije/dyw125</pub-id><?supplied-pmid 27864403?><pub-id pub-id-type="pmid">27864403</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Brookes</surname><given-names>ST</given-names></string-name>, <string-name><surname>Whitley</surname><given-names>E</given-names></string-name>, <string-name><surname>Peters</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Mulheran</surname><given-names>PA</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Davey Smith</surname><given-names>G</given-names></string-name></person-group>. <article-title>Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives</article-title>. <source>Health Technol Assess</source>. <year>2001</year>;<volume>5</volume>(<issue>33</issue>):<fpage>1</fpage>-<lpage>56</lpage>. doi:<pub-id pub-id-type="doi">10.3310/hta5330</pub-id><?supplied-pmid 11701102?><pub-id pub-id-type="pmid">11701102</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ou</surname><given-names>YN</given-names></string-name>, <string-name><surname>Tan</surname><given-names>CC</given-names></string-name>, <string-name><surname>Shen</surname><given-names>XN</given-names></string-name>, <etal/></person-group>. <article-title>Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies</article-title>. <source>Hypertension</source>. <year>2020</year>;<volume>76</volume>(<issue>1</issue>):<fpage>217</fpage>-<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.14993</pub-id><?supplied-pmid 32450739?><pub-id pub-id-type="pmid">32450739</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Davis-Plourde</surname><given-names>KL</given-names></string-name>, <string-name><surname>Sedaghat</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Antihypertensive medications and risk for incident dementia and Alzheimer’s disease: a meta-analysis of individual participant data from prospective cohort studies</article-title>. <source>Lancet Neurol</source>. <year>2020</year>;<volume>19</volume>(<issue>1</issue>):<fpage>61</fpage>-<lpage>70</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(19)30393-X</pub-id><?supplied-pmid 31706889?><pub-id pub-id-type="pmid">31706889</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gottesman</surname><given-names>RF</given-names></string-name>, <string-name><surname>Albert</surname><given-names>MS</given-names></string-name>, <string-name><surname>Alonso</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort</article-title>. <source>JAMA Neurol</source>. <year>2017</year>;<volume>74</volume>(<issue>10</issue>):<fpage>1246</fpage>-<lpage>1254</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2017.1658</pub-id><?supplied-pmid 28783817?><pub-id pub-id-type="pmid">28783817</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McGrath</surname><given-names>ER</given-names></string-name>, <string-name><surname>Beiser</surname><given-names>AS</given-names></string-name>, <string-name><surname>DeCarli</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Blood pressure from mid- to late life and risk of incident dementia</article-title>. <source>Neurology</source>. <year>2017</year>;<volume>89</volume>(<issue>24</issue>):<fpage>2447</fpage>-<lpage>2454</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000004741</pub-id><?supplied-pmid 29117954?><pub-id pub-id-type="pmid">29117954</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Abell</surname><given-names>JG</given-names></string-name>, <string-name><surname>Kivimäki</surname><given-names>M</given-names></string-name>, <string-name><surname>Dugravot</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension</article-title>. <source>Eur Heart J</source>. <year>2018</year>;<volume>39</volume>(<issue>33</issue>):<fpage>3119</fpage>-<lpage>3125</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehy288</pub-id><?supplied-pmid 29901708?><pub-id pub-id-type="pmid">29901708</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bosch</surname><given-names>J</given-names></string-name>, <string-name><surname>O’Donnell</surname><given-names>M</given-names></string-name>, <string-name><surname>Swaminathan</surname><given-names>B</given-names></string-name>, <etal/>; <collab>HOPE-3 Investigators</collab></person-group>. <article-title>Effects of blood pressure and lipid lowering on cognition: results from the HOPE-3 study</article-title>. <source>Neurology</source>. <year>2019</year>;<volume>92</volume>(<issue>13</issue>):<fpage>e1435</fpage>-<lpage>e1446</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000007174</pub-id><?supplied-pmid 30814321?><pub-id pub-id-type="pmid">30814321</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230445r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name><surname>Gidding</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Potential US population impact of the 2017 ACC/AHA High Blood Pressure Guideline</article-title>. <source>Circulation</source>. <year>2018</year>;<volume>137</volume>(<issue>2</issue>):<fpage>109</fpage>-<lpage>118</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.032582</pub-id><?supplied-pmid 29133599?><pub-id pub-id-type="pmid">29133599</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI230445-1">
              <supplementary-material id="note-ZOI230445-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2314443-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eMethods.</bold> Study Data and Methods</p>
                  <p><bold>eTable 1.</bold> SPRINT Cognitive Battery Components</p>
                  <p><bold>eTable 2.</bold> Feature Sets Used in Estimation Models</p>
                  <p><bold>eTable 3.</bold> Observed Risks of the Benefit of the Primary Outcome (Total Time for PD, Amnestic MCI, or Death) and Estimated and Observed Risk Differences With Intensive vs Standard Blood Pressure Control by Tertiles of the Estimated Benefit in SPRINT for Secondary Outcome: Occurrence of Probable Dementia, Amnestic MCI, or Death</p>
                  <p><bold>eTable 4.</bold> Observed Risks of the Benefit of the Primary Outcome (Total Time for PD, Amnestic MCI, or Death) and Estimated and Observed Risk Differences With Intensive vs Standard Blood Pressure Control by Tertiles of the Estimated Benefit in SPRINT for Secondary Outcome: Probable Dementia or Death</p>
                  <p><bold>eTable 5.</bold> Observed Risks of the Benefit of the Primary Outcome (Total Time for PD, Amnestic MCI, or Death) and Estimated and Observed Risk Differences With Intensive vs Standard Blood Pressure Control by Tertiles of the Estimated Benefit in SPRINT for Secondary Outcome: Probable Dementia, Protocol-Defined MCI, or Death</p>
                  <p><bold>eTable 6.</bold> Comparing Estimation Performance of Models Used to Estimate Benefit for All Outcomes Using C Statistic</p>
                  <p><bold>eFigure 1.</bold> Timeline for Follow-up Cognitive Assessment in SPRINT</p>
                  <p><bold>eFigure 2.</bold> Calibration Plots Showing the Observed Absolute Risks Within Deciles of Estimated Risk at 4.13 Years Follow-up for the Primary Cognitive Outcome Using the Augmented Reduced Set</p>
                  <p><bold>eFigure 3.</bold> Calibration Plots Showing the Observed Absolute Risks Within Deciles of Estimated Risk at 4.13 Years Follow-up for the Primary Cognitive Outcome Using the Basic Reduced Set</p>
                  <p><bold>eFigure 4.</bold> Bar Graph Showing the Strength of Association of Each of the Factors in Each Feature Set With Cognitive Outcomes Benefit Expressed as the Standardized Univariate Hazard Ratios Associated With Each Outcome</p>
                  <p><bold>eFigure 5.</bold> Risk Magnification Plot Showing the Estimated Magnitude of Benefit With Intensive vs Standard Systolic BP Treatment Across a Range of Estimated Baseline Risk Using the Augmented Reduced Set</p>
                  <p><bold>eFigure 6.</bold> Risk Magnification Plot Showing the Estimated Magnitude of Benefit With Intensive vs Standard Systolic BP Treatment Across a Range of Estimated Baseline Risk Using the Basic Reduced Set</p>
                </caption>
                <media xlink:href="jamanetwopen-e2314443-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e2314443-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
